Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the ...

Despite the discontinuations, CEO Pascal Soriot said AstraZeneca’s December 2020 acquisition of Alexion was a “fantastic” ...

AstraZeneca Pharma India plans to sell its 64-acre Bengaluru facility as part of a strategic review by its parent company.

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Now, let's look back a bit. On December 8, 2024, AstraZeneca announced that an AMPLIFY Phase III trial evaluating the efficacy and safety profile of the combination of Calquence and venetoclax met ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their response to immunotherapy-based treatments. The device, which has already ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

AstraZeneca has received approval from the US Food and Drug ... or placebo plus bendamustine and Rituxan. Efficacy was measured by progression-free survival (PFS) and evaluated by an independent ...

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...